<p>Sarepta Therapeutics, Inc.（NASDAQ:SRPT - 獲取免費報告）首席財務官 Ian Michael Estepan 在 8 月 30 日星期五的交易中出售了 5,985 股公司股票。這些股票的平均價格為 137.36 美元，總交易額為 822,099.60 美元。此次交易後，首席財務官直接持有公司 33,946 股股份，價值約 4,662,822.56 美元。該交易已在向美國證券交易委員會（SEC）提交的法律文件中披露，可通過 SEC 網站查閲。</p>
<p>獲取 <strong>Sarepta Therapeutics</strong> 警報：</p>
<h2>Sarepta Therapeutics 股價下跌 0.5%</h2>
<ul>
<li>這家早期生物科技公司股票上漲 400% — 您現在應該購買嗎？</li>
</ul>
<p>Sarepta Therapeutics 股票在週二的午盤交易中下跌 0.68 美元，報 135.10 美元。該公司股票的交易量為 1,186,505 股，相比平均交易量 1,346,542 股。該公司的資產負債比率為 1.05，流動比率為 3.90，速動比率為 3.19。該股市值為 127.7 億美元，市盈率為 1,234.36，貝塔係數為 0.89。該公司的 50 天移動平均價格為 144.46 美元，200 天移動平均價格為 133.13 美元。Sarepta Therapeutics, Inc.的 12 個月最低價為 55.25 美元，最高價為 173.25 美元。</p>
<p>Sarepta Therapeutics（NASDAQ:SRPT - 獲取免費報告）於 8 月 7 日星期三發佈了季度財報。這家生物技術公司報告稱該季度每股收益為 0.07 美元，超過了 0.01 美元的共識預期。該季度公司營收為 3.629 億美元，低於 3.9438 億美元的共識預期。Sarepta Therapeutics 的淨利潤率為 3.14%，淨資產收益率為 5.32%。公司季度營收同比增長 38.9%。在去年同期，公司每股虧損為（0.27）美元。分析師預計，Sarepta Therapeutics, Inc.今年將實現 1.47 美元的每股收益。</p>
<h2>對 Sarepta Therapeutics 的對沖基金觀點</h2>
<ul>
<li>Sarepta Therapeutics 股價因 FDA 批准而飆升</li>
</ul>
<p>一些對沖基金和其他機構投資者最近調整了他們對 SRPT 的持股。Capital International Investors 在去年第四季度增持了 Sarepta Therapeutics 股票 160.0%，現在持有 474.1485 萬股這家生物技術公司的股票，價值 457,221,000 美元，在上個季度增持了 291.7797 萬股。Farallon Capital Management LLC 在今年第一季度將其對 Sarepta Therapeutics 的持股增加了 102.8%。Farallon Capital Management LLC 現在持有 245.35 萬股這家生物技術公司的股票，價值 317,630,000 美元，在上個季度增持了 124.3427 萬股。挪威中央銀行在去年第四季度買入了 Sarepta Therapeutics 的新頭寸，價值約 80,697,000 美元。加拿大新斯科舍銀行在去年第四季度買入了 Sarepta Therapeutics 的新頭寸，價值約 50,990,000 美元。最後，Avoro Capital Advisors LLC 在去年第四季度將其對 Sarepta Therapeutics 的持股增加了 7.9%。Avoro Capital Advisors LLC 現在持有 434.4444 萬股這家生物技術公司的股票，價值 418,935,000 美元，在上個季度增持了 31.9444 萬股。86.68% 的股份由機構投資者持有。</p>
<h2>分析師的升級和降級</h2>
<p>許多股票研究分析師已經發布了關於 SRPT 股票的報告。摩根大通在 6 月 21 日星期五重申了對 Sarepta Therapeutics 股票的 “增持” 評級，並設定了 165.00 美元的目標價。Oppenheimer 將 Sarepta Therapeutics 股票的評級從 “市場表現” 升級為 “表現優異”，併為該公司設定了 180.00 美元的價格目標。摩根大通在 6 月 24 日星期一將 Sarepta Therapeutics 股票的目標價從 170.00 美元提高到 200.00 美元，並給予該公司 “表現優異” 評級。美國銀行將 Sarepta Therapeutics 股票的目標價從 166.00 美元提高到 213.00 美元，並給予該公司 “買入” 評級。最後，花旗集團將 Sarepta Therapeutics 股票的目標價從 176.00 美元降至 160.00 美元，併為該公司設定 “中性” 評級。三位投資分析師對該股票給予持有評級，十六位對該公司股票給予買入評級。根據 MarketBeat 的數據，該股目前的平均評級為 “中等買入”，平均目標價為 186.22 美元。</p>
<p><strong>閲讀我們對 Sarepta Therapeutics 的最新股票分析</strong></p>
<h2>關於 Sarepta Therapeutics（獲取免費報告）</h2>
<p>Sarepta Therapeutics, Inc.是一家商業化階段的生物製藥公司，專注於發現和開發 RNA 靶向治療、基因療法和其他遺傳治療模式，用於治療罕見疾病。該公司提供 EXONDYS 51 注射劑，用於治療確診為可進行外顯子 51 跳躍的肌營養不良（杜欣氏肌肉營養不良）患者；VYONDYS 53，用於治療確診為可進行外顯子 53 跳躍的杜欣氏肌肉營養不良患者；AMONDYS 45，用於治療確診為可進行外顯子 45 跳躍的杜欣氏肌肉營養不良患者；以及 ELEVIDYS，一種基於腺相關病毒的基因療法，用於治療 4 至 5 歲的行走型小兒杜欣氏肌肉營養不良患者。</p>
<h2>閲讀更多</h2>
<ul>
<li>我們喜歡的五隻股票勝過 Sarepta Therapeutics</li>
<li>技術指標如何幫助您找到超賣股票</li>
<li>內部人士正在購買的 3 只小市值股票</li>
<li>哪些華爾街分析師最準確？</li>
<li>分析師預測西部數據的巨大上漲 — 不要錯過</li>
<li>3 只小市值股票的巨大回報潛力</li>
<li>今天市場上看漲投資者必須擁有的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA"/></p>
<p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過了 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ Tim Sykes 緊急交易警報：“立即採取行動”（來自 Timothy Sykes）(廣告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4"/></p>
<h2>您現在是否應該投資$1,000 在 Sarepta 醫療？</h2>
<p>在考慮 Sarepta 醫療之前，您應該聽聽這個消息。</p>
<p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票清單...而 Sarepta 醫療不在其中。</p>
<p>雖然 Sarepta 醫療目前在分析師中擁有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Sarepta醫療

<p>薩雷普塔治療公司首席財務官伊恩·邁克爾·埃斯特潘以平均價格為 4.36 美元出售了公司的 5985 股股票，總價值為 26,099.60 美元。交易完成後，他持有 33,946 股股票，價值約為 162,822.56 美元。該交易已在美國證券交易委員會（SEC）的申報文件中披露。公司股價在午間交易中下跌了 0.5%，至 11.10 美元</p>

<p>Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) CFO Ian Michael Estepan sold 5,985 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc.（NASDAQ:SRPT - 獲取免費報告）首席財務官 Ian Michael Estepan 在 8 月 30 日星期五的交易中出售了 5,985 股公司股票。這些股票的平均價格為 137.36 美元，總交易額為 822,099.60 美元。此次交易後，首席財務官直接持有公司 33,946 股股份，價值約 4,662,822.56 美元。該交易已在向美國證券交易委員會（SEC）提交的法律文件中披露，可通過 SEC 網站查閲。</p>
</div><p>Get <strong>Sarepta Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Sarepta Therapeutics</strong> 警報：</p>
</div><h2>Sarepta Therapeutics Trading Down 0.5 %</h2>
<ul>
<li>This Early-Stage Biotech Stock Is Up 400% — Should You Buy Now?</li>
</ul>
<div class="lb-trans"><h2>Sarepta Therapeutics 股價下跌 0.5%</h2>
<ul>
<li>這家早期生物科技公司股票上漲 400% — 您現在應該購買嗎？</li>
</ul>
</div><p>Sarepta Therapeutics stock traded down $0.68 during mid-day trading on Tuesday, hitting $135.10. The company's stock had a trading volume of 1,186,505 shares, compared to its average volume of 1,346,542. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The stock has a market cap of $12.77 billion, a price-to-earnings ratio of 1,234.36 and a beta of 0.89. The business has a 50 day moving average price of $144.46 and a 200-day moving average price of $133.13. Sarepta Therapeutics, Inc. has a 12 month low of $55.25 and a 12 month high of $173.25.</p>
<div class="lb-trans"><p>Sarepta Therapeutics 股票在週二的午盤交易中下跌 0.68 美元，報 135.10 美元。該公司股票的交易量為 1,186,505 股，相比平均交易量 1,346,542 股。該公司的資產負債比率為 1.05，流動比率為 3.90，速動比率為 3.19。該股市值為 127.7 億美元，市盈率為 1,234.36，貝塔係數為 0.89。該公司的 50 天移動平均價格為 144.46 美元，200 天移動平均價格為 133.13 美元。Sarepta Therapeutics, Inc.的 12 個月最低價為 55.25 美元，最高價為 173.25 美元。</p>
</div><p>Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. The firm had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The company's quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.27) earnings per share. As a group, analysts forecast that Sarepta Therapeutics, Inc. will post 1.47 EPS for the current year.</p>
<div class="lb-trans"><p>Sarepta Therapeutics（NASDAQ:SRPT - 獲取免費報告）於 8 月 7 日星期三發佈了季度財報。這家生物技術公司報告稱該季度每股收益為 0.07 美元，超過了 0.01 美元的共識預期。該季度公司營收為 3.629 億美元，低於 3.9438 億美元的共識預期。Sarepta Therapeutics 的淨利潤率為 3.14%，淨資產收益率為 5.32%。公司季度營收同比增長 38.9%。在去年同期，公司每股虧損為（0.27）美元。分析師預計，Sarepta Therapeutics, Inc.今年將實現 1.47 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Sarepta Therapeutics</h2>
<ul>
<li>Sarepta Therapeutics Stock Soars on FDA Approval</li>
</ul>
<div class="lb-trans"><h2>對 Sarepta Therapeutics 的對沖基金觀點</h2>
<ul>
<li>Sarepta Therapeutics 股價因 FDA 批准而飆升</li>
</ul>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of SRPT. Capital International Investors raised its stake in shares of Sarepta Therapeutics by 160.0% during the fourth quarter. Capital International Investors now owns 4,741,485 shares of the biotechnology company's stock valued at $457,221,000 after acquiring an additional 2,917,797 shares during the last quarter. Farallon Capital Management LLC raised its stake in Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company's stock worth $317,630,000 after buying an additional 1,243,427 shares in the last quarter. Norges Bank bought a new position in Sarepta Therapeutics in the fourth quarter worth about $80,697,000. Bank of Nova Scotia bought a new position in Sarepta Therapeutics in the fourth quarter worth about $50,990,000. Finally, Avoro Capital Advisors LLC raised its stake in Sarepta Therapeutics by 7.9% in the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company's stock worth $418,935,000 after buying an additional 319,444 shares in the last quarter. 86.68% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>一些對沖基金和其他機構投資者最近調整了他們對 SRPT 的持股。Capital International Investors 在去年第四季度增持了 Sarepta Therapeutics 股票 160.0%，現在持有 474.1485 萬股這家生物技術公司的股票，價值 457,221,000 美元，在上個季度增持了 291.7797 萬股。Farallon Capital Management LLC 在今年第一季度將其對 Sarepta Therapeutics 的持股增加了 102.8%。Farallon Capital Management LLC 現在持有 245.35 萬股這家生物技術公司的股票，價值 317,630,000 美元，在上個季度增持了 124.3427 萬股。挪威中央銀行在去年第四季度買入了 Sarepta Therapeutics 的新頭寸，價值約 80,697,000 美元。加拿大新斯科舍銀行在去年第四季度買入了 Sarepta Therapeutics 的新頭寸，價值約 50,990,000 美元。最後，Avoro Capital Advisors LLC 在去年第四季度將其對 Sarepta Therapeutics 的持股增加了 7.9%。Avoro Capital Advisors LLC 現在持有 434.4444 萬股這家生物技術公司的股票，價值 418,935,000 美元，在上個季度增持了 31.9444 萬股。86.68% 的股份由機構投資者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師的升級和降級</h2>
</div><p>A number of equities research analysts have issued reports on SRPT shares. Morgan Stanley reissued an &#34;overweight&#34; rating and set a $165.00 target price on shares of Sarepta Therapeutics in a report on Friday, June 21st. Oppenheimer upgraded shares of Sarepta Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $180.00 price target for the company in a research report on Tuesday, May 14th. BMO Capital Markets boosted their price target on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, June 24th. Bank of America boosted their price target on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, June 21st. Finally, Citigroup reduced their price target on shares of Sarepta Therapeutics from $176.00 to $160.00 and set a &#34;neutral&#34; rating for the company in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $186.22.</p>
<ul>
<li>PepGen soars on Sarepta Therapeutics’ Duchenne drug phase 2 data</li>
</ul>
<div class="lb-trans"><p>許多股票研究分析師已經發布了關於 SRPT 股票的報告。摩根大通在 6 月 21 日星期五重申了對 Sarepta Therapeutics 股票的 “增持” 評級，並設定了 165.00 美元的目標價。Oppenheimer 將 Sarepta Therapeutics 股票的評級從 “市場表現” 升級為 “表現優異”，併為該公司設定了 180.00 美元的價格目標。摩根大通在 6 月 24 日星期一將 Sarepta Therapeutics 股票的目標價從 170.00 美元提高到 200.00 美元，並給予該公司 “表現優異” 評級。美國銀行將 Sarepta Therapeutics 股票的目標價從 166.00 美元提高到 213.00 美元，並給予該公司 “買入” 評級。最後，花旗集團將 Sarepta Therapeutics 股票的目標價從 176.00 美元降至 160.00 美元，併為該公司設定 “中性” 評級。三位投資分析師對該股票給予持有評級，十六位對該公司股票給予買入評級。根據 MarketBeat 的數據，該股目前的平均評級為 “中等買入”，平均目標價為 186.22 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Sarepta Therapeutics</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Sarepta Therapeutics 的最新股票分析</strong></p>
</div><h2>About Sarepta Therapeutics (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Sarepta Therapeutics（獲取免費報告）</h2>
</div><p>Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.</p>
<div class="lb-trans"><p>Sarepta Therapeutics, Inc.是一家商業化階段的生物製藥公司，專注於發現和開發 RNA 靶向治療、基因療法和其他遺傳治療模式，用於治療罕見疾病。該公司提供 EXONDYS 51 注射劑，用於治療確診為可進行外顯子 51 跳躍的肌營養不良（杜欣氏肌肉營養不良）患者；VYONDYS 53，用於治療確診為可進行外顯子 53 跳躍的杜欣氏肌肉營養不良患者；AMONDYS 45，用於治療確診為可進行外顯子 45 跳躍的杜欣氏肌肉營養不良患者；以及 ELEVIDYS，一種基於腺相關病毒的基因療法，用於治療 4 至 5 歲的行走型小兒杜欣氏肌肉營養不良患者。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than Sarepta Therapeutics</li>
<li>How Technical Indicators Can Help You Find Oversold Stocks</li>
<li>3 Small Cap Stocks That Insiders Are Buying</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>Analysts Forecast Big Upside for Western Digital—Don’t Miss Out</li>
<li>3 Small Caps With Big Return Potential</li>
<li>3 Must-Own Stocks for Bullish Investors in Today's Market</li>
</ul>
<div class="lb-trans"><h2>閲讀更多</h2>
<ul>
<li>我們喜歡的五隻股票勝過 Sarepta Therapeutics</li>
<li>技術指標如何幫助您找到超賣股票</li>
<li>內部人士正在購買的 3 只小市值股票</li>
<li>哪些華爾街分析師最準確？</li>
<li>分析師預測西部數據的巨大上漲 — 不要錯過</li>
<li>3 只小市值股票的巨大回報潛力</li>
<li>今天市場上看漲投資者必須擁有的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U1JQVA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=SRPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和來自 MarketBeat 的金融數據生成的，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過了 MarketBeat 編輯團隊的審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Tim Sykes’ Urgent Trade Alert: “Make this move now” (From Timothy Sykes)(Ad)</p>
<div class="lb-trans"><p>→ Tim Sykes 緊急交易警報：“立即採取行動”（來自 Timothy Sykes）(廣告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzE4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9318&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Sarepta Therapeutics right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資$1,000 在 Sarepta 醫療？</h2>
</div><p>Before you consider Sarepta Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Sarepta 醫療之前，您應該聽聽這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街評級最高且表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂級分析師悄悄告訴他們的客户現在購買的股票清單...而 Sarepta 醫療不在其中。</p>
</div><p>While Sarepta Therapeutics currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Sarepta 醫療目前在分析師中擁有 “中等買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

內幕交易：Sarepta Therapeutics, Inc.（納斯達克股票代碼：SRPT）首席財務官出售了 5,985 股股票